Asthma Drugs Market Report 2026

Asthma Drugs Market Overview

• Asthma Drugs market size has reached to $24.93 billion in 2025 • Expected to grow to $33.62 billion in 2030 at a compound annual growth rate (CAGR) of 6.3% • Growth Driver: Rising Prevalence Of Respiratory Diseases Fuels Growth In The Asthma Drug Market • Market Trend: Product Innovation In The Asthma Drug Market With Launch Of Indacaterol Plus Mometasone • North America was the largest region in 2025 and Asia Pacific is the fastest growing region.

What Is Covered Under Asthma Drugs Market?

Asthma refers to a chronic lung disease that is caused by the inflammation and tightening of muscles around the airways, which makes patients suffer from effective breathing. This is caused when the airways get narrow, swollen, and blocked by excess mucus. Asthma drugs play a crucial role in managing asthma. The main types of asthma are allergic and non-allergic. Allergic asthma is a respiratory condition characterized by the constriction of airways upon exposure to an allergen, leading to difficulty in breathing. These are various trigger types for asthma such as adult-onset asthma, child-onset asthma, cough-induced asthma, exercise-induced asthma, occupational asthma, nocturnal asthma, and steroid-resistant asthma. Asthma drug are classified into classes such as bronchodilators, monoclonal antibodies, anti-inflammatory drugs, and combination drugs that are used by asthma patients and COPD patients.

What Is The Asthma Drugs Market Growth Forecast?

The asthma drugs market size is expected to see strong growth in the next few years. It will grow to $33.62 billion in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to growth in biologics & monoclonal antibodies, adoption of smart inhalers, digital health integration, expansion of preventive care programs, increasing pediatric asthma diagnosis. Major trends in the forecast period include personalized asthma treatment, telemedicine & remote patient monitoring, development of biologic and targeted therapies, inhalation device innovation, increased focus on pediatric asthma care.

Global Asthma Drugs Market Segmentation

1) By Type Of Asthma: Allergic, Non-Allergic 2) By Asthma Trigger Type: Adult-Onset Asthma, Child-Onset Asthma, Cough-Induced Asthma, Exercise-Induced Asthma, Occupational Asthma, Nocturnal Asthma, Steroid-Resistant Asthma 3) By Therapy: Preventive 4) By Drug Class: Bronchodilators, Monoclonal Antibodies, Anti-Inflammatory Drugs, Combination Drugs 5) By End-User: Asthma Patients Subsegments: 1) By Allergic: Inhaled Corticosteroids (ICS), Leukotriene Receptor Antagonists (LTRAs), Monoclonal Antibodies 2) By Non-Allergic: Short-Acting Beta Agonists (SABAs), Long-Acting Beta Agonists (LABAs), Oral Corticosteroids

What Is The Driver Of The Asthma Drugs Market?

The rising prevalence of respiratory diseases will boost the asthma drug market. Respiratory diseases are medical conditions that affect the respiratory system, which includes the lungs, bronchi, trachea, larynx, pharynx, and nasal passages. The prevalence of respiratory diseases drives the use of asthma drugs to manage and alleviate symptoms associated with respiratory conditions. As respiratory diseases become more widespread, particularly conditions like asthma characterized by chronic inflammation and airway constriction, the demand for effective therapeutic interventions increases. For instance, in December 2023, according to a research study published by JAMA Network Open, a medical journal by the American Medical Association, the global burden of chronic obstructive pulmonary disease (COPD) projected that the cases worldwide could reach nearly 600 million by 2050, marking a 23% increase in prevalence. Therefore, the rising prevalence of respiratory diseases will drive the asthma drug industry forward.

Key Players In The Global Asthma Drugs Market

Major companies operating in the asthma drugs market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., Sanofi S.A., AstraZeneca PLC., GlaxoSmithKline PLC., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Novartis International AG, Mylan N.V., Cipla Limited, Chiesi Farmaceutici S.p.A., Sun Pharmaceutical Industries Limited, Hikma Pharmaceuticals, Mundipharma International Limited, Lupin Limited, Glenmark Pharmaceuticals Limited, Hetero Drugs Limited, Alembic Pharmaceuticals Limited, Sunovion Pharmaceuticals Inc., Amphastar Pharmaceuticals Inc., Beximco Pharmaceuticals Ltd., Innoviva Inc., Vectura Group, Circassia Group PLC, Pulmatrix Inc.

Global Asthma Drugs Market Trends and Insights

Major companies operating in the asthma drug market are focused on product innovation, such as fixed-dose triple-drug combinations, to improve lung function, better manage symptoms, and reduce exacerbations in patients with uncontrolled asthma. Fixed-dose triple-drug combinations combine multiple therapeutic agents into a single inhalation therapy to enhance treatment adherence and efficacy. For instance, in January 2023, Lupin Ltd., an India-based pharmaceutical company, launched DIFIZMA, a fixed-dose combination of indacaterol, glycopyrronium, and mometasone, for the management of inadequately controlled asthma in adults and adolescents twelve years and older. Approved by the Drug Controller General of India (DCGI), DIFIZMA expanded Lupin’s respiratory portfolio as the only fixed-dose triple-drug combination for asthma patients requiring improved symptom control. Lupin specializes in developing and manufacturing a wide range of pharmaceutical products, including inhalation therapies for respiratory disorders.

What Are Latest Mergers And Acquisitions In The Asthma Drugs Market?

In February 2024, GSK plc, a UK-based pharmaceutical industry company, acquired Aiolos Bio for an undisclosed amount. Through this acquisition, GSK gains access to AIO 001, a potentially best-in-class, long-acting anti-TSLP monoclonal antibody that is ready to enter Phase II clinical development for the treatment of adult patients with asthma. AIO-001’s long half-life could allow dosing every six months, potentially redefining the standard of care, especially for the ~40% of severe asthma patients with low T2 inflammation. Aiolos Bio is a US-based clinical-stage biotech company working on a drug for asthma.

Regional Insights

North America was the largest region in the asthma drugs market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Asthma Drugs Market?

The asthma drugs market consists of sales of drugs such as bronchodilators (beta-2 agonists), monoclonal antibodies (omalizumab, mepolizumab), and anti-inflammatory drugs (budesonide, ciclesonide), used for the treatment of asthma in patients of all ages. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Asthma Drugs Market Report 2026?

The asthma drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the asthma drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.